FDA Approvals - Episode 2

FDA Approval of Second Dosing Schedule of Nivolumab

EP. 1: FDA Approval for Lutathera in Neuroendocrine Tumors
Now Viewing
EP. 2: FDA Approval of Second Dosing Schedule of Nivolumab
EP. 3: FDA Approval of Frontline Nivolumab/Ipilimumab Combo in RCC
EP. 4: FDA Approval of Durvalumab for Stage III Unresectable NSCLC
EP. 5: FDA Approval of Brentuximab Vedotin Plus AVD in Classical Hodgkin Lymphoma
EP. 6: FDA Approval of Frontline Osimertinib in Frontline EGFR-Mutant NSCLC
EP. 7: FDA Approval of Adjuvant Dabrafenib/Trametinib in BRAF+ Melanoma
EP. 8: FDA Approval of Frontline Daratumumab Plus VMP in Multiple Myeloma

Hello and welcome to OncLive News Network, Breaking News. I'm Gina Columbus.

The FDA has approved a second dosing schedule for the PD-1 inhibitor nivolumab across all of the PD-1 inhibitor's monotherapy indications. This now allows physicians to prescribe the new dosing schedule of 480 mg of nivolumab every 4 weeks.

Nivolumab is currently approved as a single agent for advanced melanoma, advanced non-small cell lung cancer, advanced renal cell carcinoma, metastatic urothelial carcinoma, Hodgkin lymphoma, and advanced head and neck squamous cell carcinoma.

For more breaking news, subscribe to email alerts from OncLive.com. Thank you for watching! I'm Gina Columbus.

Related Content:

FDA Approvals
FDA Approval of Frontline Daratumumab Plus VMP in Multiple Myeloma
FDA Approval of Adjuvant Dabrafenib/Trametinib in BRAF+ Melanoma
FDA Approval of Frontline Osimertinib in Frontline EGFR-Mutant NSCLC